• contact
  • home
  • about
    • our history
    • management
    • board of directors
    • advisors
  • approach
  • pipeline
  • news & insights
    • presentations
    • press releases
    • references (PRL-02)
    • references (CGS-200-5)
  • careers
  • contact
  • Menu
  • newsworthy &
    insightful

    Stay updated and informed about all things Propella.

Press Release: Vizuri Health Sciences LLC to Present CGS-200-5 Knee Pain Results at the American College of Rheumatology Annual Meeting

/in press releases /by altusdevsite_4grsdf

Vizuri Health Sciences LLC to Present CGS-200-5 Knee Pain Results at the American College of Rheumatology Annual Meeting

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 altusdevsite_4grsdf https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg altusdevsite_4grsdf2019-10-29 18:25:002021-09-09 15:22:45Press Release: Vizuri Health Sciences LLC to Present CGS-200-5 Knee Pain Results at the American College of Rheumatology Annual Meeting

Press Release: Vizuri Health Sciences LLC Granted New US Patent for Novel Topical Analgesic Formulations Containing Capsaicin

/in press releases /by altusdevsite_4grsdf

Vizuri Health Sciences LLC Granted New US Patent for Novel Topical Analgesic Formulations Containing Capsaicin

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 altusdevsite_4grsdf https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg altusdevsite_4grsdf2018-07-16 19:58:222021-09-09 15:22:52Press Release: Vizuri Health Sciences LLC Granted New US Patent for Novel Topical Analgesic Formulations Containing Capsaicin

Press Release: Vizuri Health Sciences LLC Initiates a U.S. Phase 2 Osteoarthritis (OA) Knee Pain Study with Prescription-Strength Topical Capsaicin Formulation, CGS-200

/1 Comment/in press releases /by altusdevsite_4grsdf

Press Release: Vizuri Health Sciences LLC Initiates a U.S. Phase 2 Osteoarthritis (OA) Knee Pain Study with Prescription-Strength Topical Capsaicin Formulation, CGS-200 June 11, 2018 07:58 AM Eastern Daylight Time FAIRFAX, Va.–(EON: Enhanced Online News)–Vizuri Health Sciences LLC, a pharmaceutical and over-the-counter (OTC) product development company, today announced the initiation of clinical study VZU00025: A Phase […]

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 altusdevsite_4grsdf https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg altusdevsite_4grsdf2018-06-11 07:58:232021-09-09 15:22:59Press Release: Vizuri Health Sciences LLC Initiates a U.S. Phase 2 Osteoarthritis (OA) Knee Pain Study with Prescription-Strength Topical Capsaicin Formulation, CGS-200
Page 7 of 7«‹567

categories

  • presentations
  • press releases
  • references (CGS-200-5)
  • references (PRL-02)
  • home
  • about
  • approach
  • pipeline
  • news & insights
  • careers
  • contact
© 2020-2023 Propella Therapeutics, Inc. / all rights reserved
  • privacy policy
  • terms of use
  • copyright policy
Scroll to top